Another lawsuit, joining thousands consolidated into an Actos multidistrict litigation, was just brought by a Pennsylvania man over Type 2 diabetes drug, Actos (pioglitazone). The man alleges that Actos caused his bladder cancer. Actos was approved by the U.S. Food and Drug Administration (FDA) in 1999.
According to the complaint, the plaintiff began taking Actos in November 2003 to treat his Type 2 diabetes. By August 2006, the plaintiff was diagnosed with bladder cancer. The lawsuit alleges that Actos caused the man’s bladder cancer because of its defective nature and that the defendants were aware of the risk of bladder cancer associated with Actos but neglected to advise consumers so that financial interests would be preserved.
The plaintiff also alleges that Actos caused him pain and suffering, emotional distress, and economic damages in the form of medical expenses and lost wages. The lawsuit also seek damages for loss of consortium on behalf of the man’s spouse.
In June 2011, the FDA warned that taking Actos for more than a year could significantly increase the risk of developing bladder cancer and the safety label on Actos was updated to address this risk. Other research also supports the link between Actos and bladder cancer. For example, last May, a study published in the British Medical Journal revealed that Actos users were twice as likely to develop bladder cancer after taking the medication for two years. That July, the Canadian Medical Association Journal found that patients taking Actos were 22 percent likelier to develop bladder cancer.
Some of the symptoms of bladder cancer include blood in the urine, frequent urination, or feeling pain when urinating. To confirm cancer of the bladder, testing the urine for blood or abnormal cells and undergoing a bladder cytoscopy to view the bladder and obtain cells are generally conducted, WebMD says. If bladder cancer is confirmed, the stage of that cancer determines the treatment, which may include surgery to remove the cancer, chemotherapy and/or radiation therapy to destroy cancer cells, immunotherapy to attack bladder cancer cells, and/or bladder removal. Because bladder cancer is known to return, ongoing testing and early diagnosis is critical.
The lawsuit was brought by national law firm, Parker Waichman LLP. The firm’s founding partner, Jerrold S. Parker, serves on the Plaintiffs’ Steering Committee. The lawsuit was filed on May 23rd in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1170) as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as defendants.
In the first of some 3,000 Actos injury lawsuits to go to trial, jurors found Takeda Pharmaceutical must pay $6.5 million in damages to a California man. The 79-year-old plaintiff was diagnosed with terminal cancer in 2011 and had taken Actos for more than four years. In fact, his case was heard on an expedited basis because of his grave condition. The jurors said that Takeda neglected to adequately warn consumers that Actos could cause cancer, according to The South China Morning Post.